Zydus Canada is the Canadian affiliate of Zydus Lifesciences, a global, fully integrated pharmaceutical group dedicated to providing high-quality, affordable medicines and innovative healthcare solutions. Building on the group’s extensive capabilities in generics, biosimilars, vaccines, and novel therapies, Zydus Canada will focus on expanding access to cost-effective treatments for Canadian patients while upholding Zydus’s mission to improve and save lives.

As a company, our vision, mission, and purpose exemplify our commitment to science and our dedication to care and nurturance.

Vision

Be a global life-sciences company transforming lives through pathbreaking discoveries.

Mission

To unlock new possibilities in life sciences through quality healthcare solutions that impact lives.

Purpose

Empower people with the freedom to live healthier and more fulfilled lives.

Driven by the purpose of delivering care for the patients that rely on our medications and backed by the power of innovation and science, Zydus strives to make a meaningful difference in serving patients and communities. The pillars of care, compassion, and commitment to innovation are at the heart of our core.

Zydus Lifesciences Limited, the parent company of Zydus Pharmaceuticals, is a fully integrated, global healthcare provider located in Ahmedabad, India. With a legacy of over 70 years, the company is driven by a passion for innovation and making a difference in the world of health and care. Zydus Lifesciences is India’s fourth largest pharmaceutical company with more than 30 manufacturing plants worldwide and business operations in 55 countries including, India, the US, France, Spain, Brazil, Mexico, and South Africa. As one of the key players amongst pharmaceutical manufacturing companies, Zydus Lifesciences has manufacturing capabilities across the entire pharmaceutical value chain including formulations, APIs, vaccines, biosimilars, complex products, animal health products, and wellness products. From new chemical entities to vaccines, biosimilars, novel biologics, and niche technologies, Zydus is exploring different ideas to develop differentiated medicines for the future. Zydus Lifescience’s ZyCoV-D vaccine was the world’s first plasmid DNA vaccine to be approved for human use and is currently approved in India as a two-dose regimen for adults and children aged 12 years and above. Zydus Lifesciences continues to innovate with an unswerving focus to address unmet healthcare needs and is dedicated to its mission of creating healthier, happier communities across the globe.

For more information, please visit www.zyduslife.com.